Search

Displaying results 2951 - 2960 of 10000 in total
  1. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    Human papillomavirus type 33 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

    Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNE
  2. Drug

    Human papillomavirus type 45 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10312
    ApprovedInvestigational

    Human papillomavirus type 45 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 45 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

    Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNE
  3. Drug

    Human papillomavirus type 58 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10314
    ApprovedInvestigational

    Human papillomavirus type 58 L1 capsid protein antigen is contained in Gardasil is a vaccine for intramuscular injection. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 58 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae

    Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNE
  4. Drug

    Acetyl sulfisoxazole

    go.drugbank.com/drugs/DB14033
    ApprovedVet approved

    This process causes an inhibition of bacterial folic acid synthesis and de novo synthesis of purines and pyrimidines, resulting in cell growth arrest and cell death [L2788]. … It is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].

  5. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    ) to sinus rhythm in adults. … Etripamil is a nondihydropyridine, L-type calcium channel blocker.[A275238, L54728] It is a fast-acting drug with a short duration of action.

  6. Drug

    Adefovir dipivoxil

    go.drugbank.com/drugs/DB00718
    Approved

    It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir. … Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment

  7. Drug

    Ethchlorvynol

    go.drugbank.com/drugs/DB00189
    ApprovedIllicitWithdrawn

    Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

    Synonyms: 1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol, 1-chloro-3-ethyl-1-penten-4-yn-3-ol
  8. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947]. … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity

  9. Drug

    Propiomazine

    go.drugbank.com/drugs/DB00777
    Approved

    Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. … Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism.

  10. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.